Evidence mapPaperPMID 33512261Full record

ArticleThe Journal of international medical research2021

Combined treatment with a gastric inhibitory polypeptide receptor antagonist and a peptidyl peptidase-4 inhibitor improves metabolic abnormalities in diabetic mice.

Fei Yang, Shan Dang, Hongjun Lv, Bingyin Shi

Open access · goldAbstract read
In one paragraph

Article in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Fei YangDepartment of Endocrinology, The First Affiliated Hospital of Xi'an Medical University, Xi'an Shaanxi Province, China.
Shan DangDepartment of Gastroenterology, Shaanxi Provincial Peoplès Hospital, Xi'an Shaanxi Province, China.
Hongjun LvDepartment of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Shaanxi Province, China.
Bingyin ShiDepartment of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Shaanxi Province, China.ORCID https://orcid.org/0000-0002-0005-4231
First Affiliated Hospital of Xi'an Jiaotong University · CNShaanxi Provincial People's Hospital · CNXi'an Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDipeptidyl peptidase-4 inhibition and gastric inhibitory polypeptide (GIP) receptor antagonism have therapeutic effects in type 2 diabetes mellitus. We assessed the effects of sitagliptin and Pro

methodsDiabetes was induced in C57BL/6J mice by a high-fat diet and intraperitoneal injection of streptozocin. Blood glucose was assessed weekly. Six weeks later, serum triglycerides, total cholesterol and glucose tolerance were assessed and pancreatic and adipose tissues were collected.

resultsCombination therapy with sitagliptin and Pro

conclusionsCombination therapy with Pro

Indexed as

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2AnimalsBlood GlucoseGastric Inhibitory PolypeptideInsulinMiceMice, Inbred C57BLProtease InhibitorsReceptors, Gastrointestinal HormoneBlood GlucoseGastric Inhibitory Polypeptidegastric inhibitory polypeptide receptorInsulinProtease InhibitorsReceptors, Gastrointestinal Hormonecombination therapydiabetesleptinmouse modelPro3(GIP)Sitagliptin

Identifiers

PMID33512261
PMCPMC7871083
OpenAlexW3124296988

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.